The median progression-free survival was 6.5 months, and the median overall survival was 18.3 months. The combination of savolitinib and durvalumab demonstrated activity in a phase 2 trial of patients ...

There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in ...

Clear cell RCC is the most common histologic subtype of malignant tumors of the kidney. This histology accounts for 75% of renal masses that are evaluated. 7,8 Clear cell RCC derives from the proximal ...

Symptoms of stage 3 RCC vary; some patients experience blood in the urine, flank pain, fatigue, weight loss, or a palpable ...

Real-world (RW) treatment (tx) patterns and clinical outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) in the US community setting. OCTOPUS: A retrospective, multicenter study of ...

Afinitor did not improve relapse-free survival in patients with non-clear cell renal cell carcinoma — a kidney cancer subtype linked to poor prognosis. Post-surgical Afinitor (everolimus) did not ...

Gaining weight during adulthood and greater cumulative exposure to excess body weight raises the risk for overall, aggressive, fatal, and clear cell RCC. Interestingly, a reduction in BMI of at least ...

Excess weight in mid-life is a known risk factor for kidney cancer, but new research indicates that weight patterns throughout life may also affect an individual’s likelihood of developing this ...

Renal tumor pathology has evolved considerably, expanding from two main types of renal malignant tumors to over 20 distinct types. Diagnostic criteria have advanced from purely morphological features ...